What is OCEANiC?
The TOGA OCEANIC study follows on from the ADAURA study which showed a significant improvement in DFS and OS compared to placebo.
OCEANiC will provide free access to a TKI inhibitor and aims to evaluate if chemotherapy can be omitted in patients with EGFR mutant NSCLC who are at low risk of recurrence following complete surgical resection.
How do I refer a patient?
Potential patients need ctDNA collected within 28 days of surgical resection. Additional information and participating sites can be found here.
If you have a potential participant, please contact your nearest active trial site.
Recruiting hospitals:
- Peter MacCallum Cancer Centre – Melbourne
- St Vincent’s Hospital (Melbourne) Ltd – Fitzroy
- Austin Health – Austin Hospital – Heidelberg
- Monash Medical Centre – Clayton campus – Clayton
- The Chris O’Brien Lifehouse – Camperdown
- GenesisCare – St Leonards – St Leonards
- Liverpool Hospital – Liverpool
- The Prince Charles Hospital – Chermside
- Fiona Stanley Hospital – Murdoch
If you have any questions about the OCEANiC study, please do not hesitate to contact the OCEANiC team at oceanic.study@sydney.edu.au or find out here.
